Physiomics PLC Business Update Presentation
10 Novembre 2023 - 4:14PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
10 November 2023
10 November 2023
Physiomics plc
("Physiomics" or "the Company")
Business Update
Physiomics plc (AIM: PYC), is pleased to announce that,
following today's announcement of a significant grant award from
Innovate UK and The Office for Life Sciences to support the
Company's personalised dosing programme, Dr Jim Millen and Dr Pete
Sargent will provide a business update via Investor Meet Company on
17 November 2023 at 1:00 pm GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9:00 am GMT the day before
the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Physiomicsplc via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
. Investors who already follow the Company on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PK/PD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 commercial projects, over 50 targets and 75 drugs. Clients
include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKKBDPBDDBDD
(END) Dow Jones Newswires
November 10, 2023 10:14 ET (15:14 GMT)
Physiomics (LSE:PYC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Physiomics (LSE:PYC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024